{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "26206295", "DateCompleted": {"Year": "2016", "Month": "02", "Day": "26"}, "DateRevised": {"Year": "2018", "Month": "11", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2015", "Month": "07", "Day": "25"}], "ELocationID": ["108", "10.1186/s12985-015-0339-8"], "Language": ["eng"], "Journal": {"ISSN": "1743-422X", "JournalIssue": {"Volume": "12", "PubDate": {"Year": "2015", "Month": "Jul", "Day": "25"}}, "Title": "Virology journal", "ISOAbbreviation": "Virol J"}, "ArticleTitle": "The Chinese herb-derived Sparstolonin B suppresses HIV-1 transcription.", "Pagination": {"StartPage": "108", "MedlinePgn": "108"}, "Abstract": {"AbstractText": ["The Chines herb derived Sparstolonin B, (SsnB), is a recently identified natural compound that selectively blocks TLR2- and TLR4-mediated inflammatory signaling. But it is unknown whether this compound has any effect on HIV infection.", "We found that SsnB treatment blocked HIV-1 transcription via a novel mechanism that requires the TAR region. Treatment of human T cell lines or peripheral blood mononuclear cells with SsnB at 1\u00a0\u03bcM significantly inhibited HIV production. Lastly, SsnB was able to inhibit HIV in synergy with AZT.", "These data suggest that SsnB is a novel natural compound that inhibits HIV-1 transcription and may be a new drug in the treatment of HIV infection."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 10 Huadong Road, 530011, Nanning, Guangxi Province, China. 260446391@qq.com."}], "LastName": "Deng", "ForeName": "Xin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 10 Huadong Road, 530011, Nanning, Guangxi Province, China. 1067545641@qq.com."}], "LastName": "Zhang", "ForeName": "Yaping", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 10 Huadong Road, 530011, Nanning, Guangxi Province, China. 2753933363@qq.com."}], "LastName": "Jiang", "ForeName": "Feng", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 10 Huadong Road, 530011, Nanning, Guangxi Province, China. ranchen86@163.com."}], "LastName": "Chen", "ForeName": "Ran", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 10 Huadong Road, 530011, Nanning, Guangxi Province, China. pcpeng66@163.com."}], "LastName": "Peng", "ForeName": "Peichun", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 10 Huadong Road, 530011, Nanning, Guangxi Province, China. 286449737@qq.com."}], "LastName": "Wen", "ForeName": "Bin", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 10 Huadong Road, 530011, Nanning, Guangxi Province, China. Dr_JianLiang@163.com."}], "LastName": "Liang", "ForeName": "Jian", "Initials": "J"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Virol J", "NlmUniqueID": "101231645", "ISSNLinking": "1743-422X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-HIV Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Heterocyclic Compounds, 4 or More Rings"}, {"RegistryNumber": "0", "NameOfSubstance": "sparstolonin B"}, {"RegistryNumber": "4B9XT59T7S", "NameOfSubstance": "Zidovudine"}], "MeshHeadingList": [{"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Anti-HIV Agents"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Biological Products"}, {"QualifierName": [], "DescriptorName": "Cells, Cultured"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": ["drug effects", "physiology"], "DescriptorName": "HIV-1"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Heterocyclic Compounds, 4 or More Rings"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug effects", "virology"], "DescriptorName": "T-Lymphocytes"}, {"QualifierName": ["drug effects"], "DescriptorName": "Transcription, Genetic"}, {"QualifierName": ["drug effects"], "DescriptorName": "Virus Replication"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Zidovudine"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990;61(2):213\u201322. doi: 10.1016/0092-8674(90)90802-L.", "ArticleIdList": ["10.1016/0092-8674(90)90802-L", "2331748"]}, {"Citation": "Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 1991;254(5030):423\u20137. doi: 10.1126/science.1925601.", "ArticleIdList": ["10.1126/science.1925601", "PMC9524215", "1925601"]}, {"Citation": "McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler-Campbell JA, et al. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol. 1985;135(5):3151\u201362.", "ArticleIdList": ["2995487"]}, {"Citation": "Ganesh L, Burstein E, Guha-Niyogi A, Louder MK, Mascola JR, Klomp LW, et al. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature. 2003;426(6968):853\u20137. doi: 10.1038/nature02171.", "ArticleIdList": ["10.1038/nature02171", "14685242"]}, {"Citation": "Qiu C, Xu X. H. Z. Pharmacology and clinics of Chinese material. Medica. 2008;14."}, {"Citation": "Lee SY, Choi SU, Lee JH, Lee DU, Lee KR. A new phenylpropane glycoside from the rhizome of Sparganium stoloniferum. Arch Pharm Res. 2010;33(4):515\u201321. doi: 10.1007/s12272-010-0404-1.", "ArticleIdList": ["10.1007/s12272-010-0404-1", "20422359"]}, {"Citation": "Liang Q, Wu Q, Jiang J, Duan J, Wang C, Smith MD, et al. Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem. 2011;286(30):26470\u20139. doi: 10.1074/jbc.M111.227934.", "ArticleIdList": ["10.1074/jbc.M111.227934", "PMC3143611", "21665946"]}, {"Citation": "Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46(6):1896\u2013905. doi: 10.1128/AAC.46.6.1896-1905.2002.", "ArticleIdList": ["10.1128/AAC.46.6.1896-1905.2002", "PMC127242", "12019106"]}, {"Citation": "Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R, Gaynor RB. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. Embo J. 1989;8(3):765\u201378.", "ArticleIdList": ["PMC400873", "2721501"]}, {"Citation": "Southgate CD, Green MR. The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev. 1991;5(12B):2496\u2013507. doi: 10.1101/gad.5.12b.2496.", "ArticleIdList": ["10.1101/gad.5.12b.2496", "1752440"]}, {"Citation": "Shridhar V, Chen Y, Gupta P. The CD8 antiviral factor (CAF) can suppress HIV-1 transcription from the long terminal repeat (LTR) promoter in the absence of elements upstream of the CATATAA box. Virol J. 2014;11:130. doi: 10.1186/1743-422X-11-130.", "ArticleIdList": ["10.1186/1743-422X-11-130", "PMC4223764", "25048949"]}, {"Citation": "Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J, et al. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci U S A. 1989;86(18):6925\u20139. doi: 10.1073/pnas.86.18.6925.", "ArticleIdList": ["10.1073/pnas.86.18.6925", "PMC297963", "2476805"]}, {"Citation": "Weeks KM, Ampe C, Schultz SC, Steitz TA, Crothers DM. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science. 1990;249(4974):1281\u20135. doi: 10.1126/science.2205002.", "ArticleIdList": ["10.1126/science.2205002", "2205002"]}, {"Citation": "Roy S, Delling U, Chen CH, Rosen CA, Sonenberg N. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev. 1990;4(8):1365\u201373. doi: 10.1101/gad.4.8.1365.", "ArticleIdList": ["10.1101/gad.4.8.1365", "2227414"]}, {"Citation": "Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010;85(1):1\u201318. doi: 10.1016/j.antiviral.2009.10.002.", "ArticleIdList": ["10.1016/j.antiviral.2009.10.002", "PMC2815149", "20018391"]}, {"Citation": "Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136. doi: 10.1158/0008-5472.CAN-09-1947.", "ArticleIdList": ["10.1158/0008-5472.CAN-09-1947", "20068163"]}, {"Citation": "Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47(2):331\u201385.", "ArticleIdList": ["7568331"]}, {"Citation": "Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355. doi: 10.1016/0065-2571(84)90007-4.", "ArticleIdList": ["10.1016/0065-2571(84)90007-4", "6382953"]}, {"Citation": "Eron JJ, Jr, Johnson VA, Merrill DP, Chou TC, Hirsch MS. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2\u2019,3\u2019-dideoxycytidine in vitro. Antimicrob Agents Chemother. 1992;36(7):1559\u201362. doi: 10.1128/AAC.36.7.1559.", "ArticleIdList": ["10.1128/AAC.36.7.1559", "PMC191620", "1324648"]}], "ReferenceList": []}], "History": [{"Year": "2015", "Month": "2", "Day": "18"}, {"Year": "2015", "Month": "7", "Day": "3"}, {"Year": "2015", "Month": "7", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2015", "Month": "7", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "2", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2015", "Month": "7", "Day": "25"}], "PublicationStatus": "epublish", "ArticleIdList": ["26206295", "PMC4513614", "10.1186/s12985-015-0339-8", "10.1186/s12985-015-0339-8"]}}], "PubmedBookArticle": []}